PORTFOLIO
Investing in Novel Technologies That Could Shape the Future of Healthcare
Leal Therapeutics is a biotechnology company dedicated to developing novel precision medicines for patients with high-need central nervous system disorders.
Hyku Biosciences is developing small-molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression.
UK-based company
Currently operating in stealth mode.
Stylus Medicine is developing in vivo genetic medicines to unlock cures. The company’s platform is powered by engineered recombinases that encode therapeutics with high precision.
Dualitas Therapeutics is pioneering the future of bispecific antibody therapies. Driven by its DualScreen discovery engine, Dualitas is advancing novel bispecific antibody therapies for immunological and inflammatory disease.